Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease - PubMed (original) (raw)

Case Reports

Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease

J H Kordower et al. Ann Neurol. 1999 Sep.

Abstract

As part of a safety and tolerability study, a 65-year-old man with Parkinson's disease (PD) received monthly intracerebroventricular injections of glial-derived neurotrophic factor (GDNF). His parkinsonism continued to worsen following intracerebroventricular GDNF treatment. Side effects included nausea, loss of appetite, tingling, L'hermitte's sign, intermittent hallucinations, depression, and inappropriate sexual conduct. There was no evidence of significant regeneration of nigrostriatal neurons or intraparenchymal diffusion of the intracerebroventricular GDNF to relevant brain regions. Alternative GDNF delivery systems should be explored.

PubMed Disclaimer

Cited by

Cortistatin as a Novel Multimodal Therapy for the Treatment of Parkinson's Disease.
Serrano-Martínez I, Pedreño M, Castillo-González J, Ferraz-de-Paula V, Vargas-Rodríguez P, Forte-Lago I, Caro M, Campos-Salinas J, Villadiego J, Peñalver P, Morales JC, Delgado M, González-Rey E. Serrano-Martínez I, et al. Int J Mol Sci. 2024 Jan 5;25(2):694. doi: 10.3390/ijms25020694. Int J Mol Sci. 2024. PMID: 38255772 Free PMC article.
Role of Astrocytes in Parkinson's Disease Associated with Genetic Mutations and Neurotoxicants.
Kim S, Pajarillo E, Nyarko-Danquah I, Aschner M, Lee E. Kim S, et al. Cells. 2023 Feb 15;12(4):622. doi: 10.3390/cells12040622. Cells. 2023. PMID: 36831289 Free PMC article. Review.
Glial cell response: A pathogenic factor in Parkinson's disease.
Wu DC, Tieu K, Cohen O, Choi DK, Vila M, Jackson-Lewis V, Teismann P, Przedborski S. Wu DC, et al. J Neurovirol. 2002 Dec;8(6):551-8. doi: 10.1080/13550280290100905. J Neurovirol. 2002. PMID: 12476349 Review.
Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.
Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, Burger C, Mandel RJ, Annett L, Kirik D. Eslamboli A, et al. J Neurosci. 2005 Jan 26;25(4):769-77. doi: 10.1523/JNEUROSCI.4421-04.2005. J Neurosci. 2005. PMID: 15673656 Free PMC article.
Treatment of Parkinson's disease with trophic factors.
Peterson AL, Nutt JG. Peterson AL, et al. Neurotherapeutics. 2008 Apr;5(2):270-80. doi: 10.1016/j.nurt.2008.02.003. Neurotherapeutics. 2008. PMID: 18394569 Free PMC article. Review.

Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease - PubMed (original) (raw)